Boston Scientific launches Resonate CRT-D devices in Europe

Boston Scientific has announced the European launch of its new Resonate family of cardiac resynchronisation therapy defibrillator (CRT-D) systems.

The devices, which recently received CE Mark approval, are designed for the treatment of heart failure patients and come equipped with SmartCRT technology to facilitate a more personalised approach to care.

Using SmartCRT, the systems can be calibrated to determine where, when and how to pace on a case-by-case basis, while its MultiSite Pacing technology provides three left ventricular multipoint pacing options to further improve response rates.

The product line includes the Resonate X4, Charisma X4, Vigilant X4 and Momentum X4 CRT-D devices, all of which come equipped with EnduraLife battery technology, which has been clinically proven in nine independent studies to offer industry-leading longevity of up to 14.7 years.

Professor John Morgan, chief medical officer and medical director for rhythm management at Boston Scientific in Europe, said: "We are committed to providing treatment options based on the most advanced technology for every patient and working to tackle the ongoing burden of heart failure."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.